RxCell Inc., A*STAR’s IMCB, NUS, and SERI Collaborate to Develop Cellular Therapeutics for Age-related Diseases – Business Wire

SAN FRANCISCO--(BUSINESS WIRE)--RxCell, a Bay Area-based biotechnology company focused on therapeutic applications of induced pluripotent stem cells (iPSC), together with the Agency for Science, Technology and Research (A*STAR)s Institute of Molecular and Cell Biology (IMCB), Yong Loo Lin School of Medicine at the National University of Singapore (NUS) and the Singapore Eye Research Institute (SERI), announced a co-funded collaboration to develop cellular therapeutics for age-related diseases.

Read more
Singapore-US to develop cellular therapeutics for age-related diseases – BSA bureau

RxCell to establish a Joint Lab to work with IMCB, A*STAR, NUS and SERI in Singapore RxCell, a US-based biotechnology company focused on therapeutic applications of induced pluripotent stem cells (iPSC), together with the Agency for Science, Technology and Research (A*STAR)s Institute of Molecular and Cell Biology (IMCB), Yong Loo Lin School of Medicine at the National University of Singapore (NUS) and the Singapore Eye Research Institute (SERI), has announced a co-funded collaboration to develop cellular therapeutics for age-related diseases. Through this collaboration, RxCell will contribute their clinical grade iPSC as well as hypoimmunogenic iPSC generated by their proprietary technologies which confer the advantage of being able to evade the hosts immune system and avoid an unwanted immune response. This will complement IMCBs expertise in retinal diseases and animal modelling, NUSs expertise in age-related cell therapy strategies and SERIs expertise in rabbits and non-human primates ocular disease models

Read more
Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development – GlobeNewswire

Gosselies, Belgium, 12 October 2021, 7:00 am CEST BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has appointed key experts to a Scientific Advisory Board (SAB). Bone Therapeutics has appointed the members of this SAB specifically to provide additional expert guidance on the development of Bone Therapeutics novel, next generation induced pluripotent stem cell-derived mesenchymal stromal cell (iMSC) platform.

Read more
Stem Cells & Therapies Archives – Charlotte Lozier Institute

The California based City of Hope, one of the countrys leading cancer research hospitals, recently sent out birthday greetings to the California Institute for Regenerative Medicine (CIRM), the nations leading funder apart from the federal government of stem cell research. On its 10th birthday, the California Institute for Regenerative Medicine celebrated 10 stem cell therapies that have been approved for clinical trials, including an HIV/AIDS trial at City of Hope, the message read

Read more
Stem Cell Research | Uses of Stem Cells and Ethics …

As a network of scientists and academics, we provide independent, expert-reviewed information and road-tested educational resources on stem cells and their impact on society. We also work with people affected by conditions, educators, regulators, media, healthcare professionals and policymakers to foster engagement and develop material that meets their needs.

Read more
Japan’s Fujifilm promotes industrial application of iPS cell-derived regenerative medicine – BSA bureau

Fujifilm agrees on core terms with Australian regenerative medicine venture Cynata to manufacture Cynatas iPS cell-derived regenerative medicine products Japan-based FUJIFILM Corporation has reached agreement on core terms with Australian regenerative medicine venture Cynata Therapeutics to manufacture regenerative medicine products using induced pluripotent stem (iPS) cells.

Read more
Drug that stops ALS progression found using iPS cells from patients – The Japan Times

Kyoto A drug discovered through a method using induced pluripotent stem cells, or iPS cells, from sufferers of amyotrophic lateral sclerosis (ALS) was effective in stopping the progression of the neurological disease in five out of nine patients in a clinical trial, a research team at Kyoto University said Thursday. While drugs that slow down the progression of amyotrophic lateral sclerosis, also known as Lou Gehrigs disease, have been used in the past, this is the first time that a chronic myeloid leukemia drug called bosutinib has been found to stop its progression, according to the team

Read more